KLRK1 and Crohn disease: Although not yet approved by the FDA, the anti‐NKG2D NNC0142‐0002, an antagonizing human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D receptors, has successfully completed phase 2 studies for Crohn's disease and rheumatoid arthritis [48, 49].